Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.

about

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.

Item

http://www.wikidata.org/entity/Q52571294

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@en

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@nl

type

Item

label

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@en

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@nl

prefLabel

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@en

Testing for NRAS Mutations in ...... ade Serous Ovarian Carcinomas.

@nl

P1476

Testing for NRAS Mutations in ...... rade Serous Ovarian Carcinomas

@en

P2093

Marek Grabiec

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Global cancer statistics, 2012

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

A comprehensive survey of Ras mutations in cancer.

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P304

1497879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/1497879

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Dariusz Grzanka

Pawel Sadlecki

P577

2018-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29682098

http://www.w3.org/2001/XMLSchema#string

P932

5845515

http://www.w3.org/2001/XMLSchema#string